Population pharmacokinetic analysis of
clinical study data showed that oestrogens
(from HRT) reduced ropinirole clearance by one-third.
In women already receiving
HRT, ropinirole treatment may be started using the
usual dose titration. However, a reduction in the ropinirole dosage may be needed
if
HRT is started, and an increase if it is withdrawn.